September 14, 2015

Hatchtech will pay Dr. Reddy’s $10 million upfront and potentially as much as $50 million based on milestones linked to sales targets. 

August 28, 2015

Dr. Reddy’s Laboratories on Thursday announced several senior level changes in their global management structure.

August 12, 2015

Dr. Reddy’s Laboratories has announced the launch and FDA approval of its pramipexole dihydrochloride extended release tablets.

July 14, 2015

Both Mylan and Dr. Reddy’s Laboratories have announced the launch of their generic version of dementia drug Namenda.

July 1, 2015

The new purple logo is meant to express dynamism, creativity and empathy — three values at the heart of its mission to patients, Dr. Reddy's noted in a statement.

June 15, 2015

 "As it stands now, TPP will make it harder for the U.S. generic industry to sell its products overseas," GPhA's Ralp Neas reported. 

April 1, 2015

Dr. Reddy's Laboratories on Wednesday acquired UCB's portfolio of dermatology, respiratory and pediatric products. 

March 24, 2015

Dr. Reddy’s Labs has entered into an agreement with Hetero, under which it will be licensed to distribute and market sofosbuvir tablets in 400-mg dosage strength. 

December 19, 2014

Dr. Reddy’s Laboratories has announced that it has closed the acquisition of Habitrol brand — an over-the-counter nicotine replacement therapy transdermal patch — from Novartis Consumer Health.

December 18, 2014

Dr. Reddy’s Laboratories announced Tuesday that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of the antiviral Valcyte (Valganciclovir) tablets, in the U.S. market.

December 16, 2014

Dr. Reddy's Labs announced the launch of valganciclovir tablets USP in 450-mg strength. 


November 24, 2014

Dr. Reddy's Labs on Monday announced the launch of docetaxel injection USP in 20-mg and 80-mg dosage strengths. The drug is the generic version of Taxotere.


November 20, 2014

Dr. Reddy’s Labs announced Thursday that it has launched a bioequivalent generic version of Allegra-D 12 Hour Allergy and Congestion, in the U.S. market.

November 11, 2014

Dr. Reddy's Labs received approval from the Food and Drug Administration for a generic version of Roche Holding's antiviral medication Valcyte, according to a Reuters report

October 30, 2014

Dr. Reddy's Labs on Tuesday announced the launch of sirolimus tablets in 1-mg and 2-mg dosage strengths.

September 24, 2014

Dr. Reddy's Labs on Wednesday announced the launch of levalbuterol inhalation solution, USP in 0.31-mg, 0.63-mg and 1.25-mg unit-dose vials.

July 31, 2014

Dr. Reddy's Labs announced financial results for the quarter ended June 30, which includes consolidated revenues of Rs.35.2 billion, representing year-on-year growth of 24%.

July 23, 2014

Generics supplier Camber Pharmaceuticals added two new executives to its team this week, bringing on Kirk Hessels as marketing director and Amanda Rebnicky as its sales operations director.

June 27, 2014

Dr. Reddy's Labs on Friday announced the launch of duloxetine delayed-release capsules USP in 20 mg, 30 mg and 60 mg dosage strengths.

June 25, 2014

Dr. Reddy's Labs on Wednesday announced that it has launched paricalcitol capsules in 1-mcg, 2-mcg and 4-mcg dosage strengths.

May 14, 2014

Dr. Reddy's Labs has named Satish Reddy as chairman of the board. Reddy previously held the position of vice-chairman, managing director and COO. GV Prasad will continue to serve as CEO and provide leadership to the company in an executive capacity.

May 14, 2014

Dr. Reddy’s Laboratories on Tuesday posted $2.2 billion in annual sales for the fiscal year ended March 31, representing growth of 14%.

April 23, 2014

Dr. Reddy's Labs on Wednesday announced the launch of fenofibrate capsules, USP in 43-mg and 130-mg strengths. The drug is the generic version of Antara (fenofibrate) capsules.

April 16, 2014

Dr. Reddy's Labs announced the launch of eszopiclone tablets (C-IV) in 1-mg, 2-mg and 3-mg form. The drug is the generic version of Lunesta (eszopiclone) tablets.